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Introduction: Several new treatments have been developed for psoriatic disease, an
inflammatory condition that involves skin and joints. Notwithstanding, few studies have
made direct comparisons between treatments and therefore it is difficult to select the
ideal treatment for an individual patient. The aim of this systematic review with network
meta-analysis (NMA) was to analyze available and approved biologic therapies for each
domain of psoriatic disease: skin, peripheral arthritis, axial arthritis, enthesitis, dactylitis,
and nail involvement.
Methods: Data from randomized clinical trials (RCTs) were included. A systematic review
was performed using the MEDLINE database (July 2020) using PICO criteria. Bayesian
NMA was conducted to compare the clinical efficacy of biological therapy in terms of
the American College of Rheumatology criteria (ACR, 24 weeks) and Psoriasis Area and
Severity Index (PASI, 10–16 weeks).
Results: Fifty-four RCTs were included in the systematic review. Due to the design of
the RCTs, namely, outcomes and time points, network meta-analysis was performed
for skin and peripheral arthritis domains. For the skin domain, 30 studies reporting
PASI100 were included. The peripheral arthritis domain was analyzed through ACR70
in 12 studies. From the therapies approved for both domains, secukinumab and
ixekizumab were the ones with the highest probability of reaching the proposed
outcomes. There is a lack of outcome uniformization in the dactylitis, enthesitis, and
nail domains, and therefore, an objective comparison of the studies was not feasible.
Nevertheless, secukinumab was the treatment with the best compromise between the
number of studies in each domain and the results obtained in the different outcomes.
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Conclusion: Secukinumab and ixekizumab were the treatments with the highest
probability of reaching both PASI100 and ACR70 outcomes. Due to the lack of a standard
evaluation of outcomes of the other psoriatic disease domains, a network meta-analysis
for all the domains was not possible to perform.
Keywords: psoriasis, psoriatic arthritis, psoriatic disease, biologic therapy, systematic review, network
meta-analysis
INTRODUCTION
Psoriasis (PsO) affects 1–3% of the world population. Psoriatic
arthritis (PsA) occurs in a third of the patients with PsO. These
two conditions share clinical, genetic, and pathogenic factors and
can be considered a single entity—psoriatic disease (PsD) (1–3).
PsD involves chronic inflammation of the skin, nails, and
joints (arthritis, enthesitis, dactylitis, and spondylitis) (4).
Autoimmune mechanisms are involved in PsA pathogenesis, and
this is ultimately related with the systemic nature of the disease
and raised the concept of a Systemic Psoriatic Disease. This
fact highlights the heterogeneity of the disease and the need for
optimizing its management (5).
Optimal management of PsD requires early diagnosis,
monitoring of the disease activity, and treatment with effective
and safe therapies. Over the last 20 years, targeted therapies
emerged in the treatment of PsD, namely, biologic agents such as
tumor necrosis factor inhibitors (TNFi), IL-17 inhibitors (IL-17i),
and IL-12/23 inhibitors (IL-12/23i), and small molecules, such as
Janus Kinase (JAK) or phosphodiesterase 4 (PDE4) inhibitors (6).
The Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) is a global association of more
than 500 rheumatologists, dermatologists, and patient research
partners that publish treatment recommendations for PsD
(2). The treatment of six domains—peripheral arthritis, axial
disease, enthesitis, dactylitis, skin disease, and nail disease—
are included in the recommendations directed to anyone
involved in the treatment of patients with PsD (2). Based on
these recommendations, we performed a systematic review and
network meta-analyses assessing the main results of randomized
clinical trials (RCT) including biologic therapies in the treatment
of patients with PsD.
METHODS
Literature Search
A literature search according to the Population, Intervention,
Comparator, Outcomes (PICO) framework was performed
establishing criteria for study eligibility. The population was
defined as adult (≥18 years) patients with the PsD (PsO and/or
PsA) and the intervention as any biologic therapy: adalimumab
(ADA), etanercept (ETN), infliximab (IFX), golimumab (GOL),
certolizumab (CZP), ustekinumab (UST), secukinumab (SEC),
ixekizumab (IXE), guselkumab (GUS), brodalumab (BRD),
risankizumab (RIS), and tildrakizumab (TIL), in all formulations
and treatment durations. The comparator was the same drug
(different dose or regimen), any different drug, or placebo.
Outcomes considered were American College of Rheumatology
(ACR) or Psoriasis Area Severity Index (PASI) or dactylitis
assessment or enthesitis assessment or nail psoriasis assessment.
The MEDLINE database search was performed on 1 July 2020,
with the filters “Humans,” “Clinical Trials,” “Phase III,” and
“English,” with no date limits. In line with the GRAPPA and
EULAR recommendations, we did not include abatacept in this
systematic review. In addition, as this systematic review was
focused only on biologic treatments apremilast and tofacitinib
were not analyzed.
Statistics and Network Meta-Analyses
Network meta-analyses (NMA) were carried out using the
web application CINeMA 1.9.0 (Confidence in Network Meta-
Analysis) from Cochrane (7). This application is based on a
described methodological framework that considers six domains:
within-study bias, reporting bias, indirectness, imprecision,
heterogeneity, and incoherence (8). NMAs based on the Bayesian
framework using the fixed-effects model were performed to
pool all the direct and indirect evidence together. Odds ratio
(OR) with 95% credible intervals (CrI) was used to evaluate
comparisons. Only comparisons showing high confidence in the
six domains were considered for the results.
Assessment of Bias
Assessment of bias was performed using the latest version of
RoB2—Cochrane (9).
RESULTS
A detailed flowchart with the results of the literature review
is shown in Figure 1. Out of the 232 references retrieved, 82
studies were selected for data (1, 11–57). For NMAs, only studies
reporting ACR20, ACR50, ACR70 (peripheral arthritis domain),
PASI75, PASI90, or PASI100 (skin domain) were included. For
the peripheral arthritis domain, only 24 weeks were included.
For the skin domain, results between 10 and 16 weeks were
considered. Moreover, the doses of the drugs for the systematic
review and NMAs, for the peripheral arthritis and skin domains,
were the ones approved by the regulatory authorities. The studies
included in the NMAs are identified in Table 1. Extension studies
are specified in Table 2 (48, 58–84). In Figure 2 the drugs
that have been studied specifically for each domain of PsD
were included.
Peripheral Arthritis
The peripheral arthritis domain is predominantly assessed by
instruments, such as ACR20, ACR50, and ACR70 criteria, which
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FIGURE 1 | PRIMA flow diagram. Adapted from (10).
specify the improvement of 20, 50, or 70% in the number of
tender and swollen joints, respectively, and a 20, 50, or 70%
improvement in three of the following five criteria: patient
global assessment, physician global assessment, functional ability
measure (most often Health Assessment Questionnaire—HAQ),
visual analog pain scale, and erythrocyte sedimentation rate or
C-reactive protein (85). The main results of the ACR response
in RCTs, at 24 weeks, are included in Table 3 (1, 11, 18,
24, 26, 28, 31, 32, 37, 38, 47, 51, 55). The head-to-head
comparison of the ACR responses of SEC vs. ADA at week
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TABLE 1 | RCT included in the systematic review and NMA, focusing on the outcomes of GRAPPA domains.
Study Enrolled patients NMA
Author Year N Drug Dosage Outcomes
















(14) Tyring 2007 618 ETN 50mg ④⑤⑥ YES
PLB
PHOENIX 1 (15) Leonardi 2008 766 UST 45mg ④⑤⑥ YES
UST 90mg
PLB
PHOENIX 1 (16) Papp 2008 1,230 UST 45mg ④⑤⑥ YES
UST 90mg
PLB
(17) Rich 2008 378 IFX 5 mg/kg ⑩ NO
PLB






(19) Barker 2011 868 IFX 5 mg/kg ④⑤⑥ YES
MTX 15mg
(20) Gottlieb 2011 347 BRK 200mg ⑤⑥⑦ YES
ETN 50mg
PLB
(21) Strober 2011 350 BRK 200mg ⑤⑥⑦ YES
ETN 50mg
PLB




(23) Gottlieb 2012 478 MTX + ETN 15mg + 50mg ④⑤⑥ NO





ERASURE (25) Langley 2014 738 SEC 150mg ⑤⑥⑦ YES
SEC 300mg
PLB
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TABLE 1 | Continued
Study Enrolled patients NMA
Author Year N Drug Dosage Outcomes









UNOCOVER 3 (29) Griffiths 2015 1,346 IXE 80mg 2w YES
IXE 80mg 4w ⑤⑥⑦
ETN 50mg
PLB




















CLEAR (33) Thaçi 2015 676 SEC 300mg ⑤⑥⑦ YES
UST 45/90mg
BELIEVE (34) Thaçi 2015 730 ADA 40mg ⑩ NO
PLB
AMAGINE-1 (35) Papp 2016 661 BRD 140mg ⑤⑥⑦ YES
BRD 210mg
PLB
VOYAGE 1 (36) Blauvelt 2017 837 GUS 100mg ⑤⑥⑦⑩ YES
ADA 40mg
PLB
SPIRIT-P1 (37) Mease 2017 417 IXE 80mg 2w ①②⑤ YES
IXE 80mg 4w ⑥⑦⑧
ADA 40mg ⑨⑩
PLB
SPIRIP-P2 (38) Nash 2017 363 IXE 80mg 2w ①②③ YES
IXE 80mg 4w ⑤⑥⑦
PLB ⑧⑨⑩
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TABLE 1 | Continued
Study Enrolled patients NMA
Author Year N Drug Dosage Outcomes




IXORA-S (40) Reich 2017 302 IXE 80mg ⑤⑥⑦ YES
UST 45/90mg
CLARITY (41) Bagel 2018 1102 SEC 300mg ⑤⑥⑦ YES
UST 45/90mg
(42) Elewski 2018 217 ADA 40mg ⑩ NO
PLB
UltIMMa-1 (43) Gordon 2018 506 RIS 150mg ⑤⑥⑦ YES
UST 45/90mg
PLB
UltIMMa-2 (43) Gordon 2018 491 RIS 150mg ⑤⑥⑦ YES
UST 45/90mg
PLB
CIMPASI-1 (44) Gottlieb 2018 234 CZP 200mg ⑥⑦ YES
CZP 400mg
PLB
CIMPASI-2 (44) Gottlieb 2018 227 CZP 200mg ⑥⑦ YES
CZP 400mg
PLB














SustaIMM (48) Ohtsuki 2019 171 RIS 75mg ⑤⑥⑦ YES
RIS 150mg
PLB
ECLIPSA (50) Araujo 2019 47 UST 45/90mg ⑨ NO
TNFi
IMMvent (52) Reich 2019 605 RIS 150mg ⑤⑥⑦ YES
ADA 40mg
ECLIPSE (53) Reich 2019 1048 GUS 100mg ⑤⑥⑦ YES
SEC 300mg












EXCEED (55) McInnes 2020 853 SEC 300mg ①②③⑤ NO
ADA 40mg ⑥⑦⑧⑨
(Continued)
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TABLE 1 | Continued
Study Enrolled patients NMA
Author Year N Drug Dosage Outcomes
ORION (56) Ferris 2020 78 GUS 100mg ⑤⑥⑦ YES
PLB
IMMerge (57) Warren 2020 327 RIS 150mg ⑤⑥⑦ YES
SEC 300mg
N, number; NMA, network meta-analysis; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; RCT, randomized clinical trial; ADA, adalimumab; ETN,
etanercept; INF, infliximab; GOL, golimumab; CZP, certolizumab; UST, ustekinumab; SEC, secukinumab; IXE, ixekizumab; GUS, guselkumab; BRD, brodalumab; RIS, risankizumab; TIL,
tildrakizumab; BRK, briakinumab; MTX, methotrexate; PLB, placebo.
① ACR20, ② ACR50, ③ ACR70, ④ PASI50, ⑤ PASI75, ⑥ PASI90, ⑦ PASI100, ⑧ dactylitis assessment, ⑨ enthesitis assessment, ⑩ nail assessment.
YES—the study was in NMA; NO—the study was not included in NMA.
TABLE 2 | Extension studies from RCT focusing on outcomes of GRAPPA domains.
Study Enrolled patients NMA
Author Year N Time of outcome
(weeks)
Drug Dosage Outcomes
IMPACT 2 (58) Kavanaugh 2007 200 52 IFX 5 mg/kg ①②③④
⑤⑥⑧⑨PLB
(59) Menter 2008 1,212 52 ADA 40mg ⑥⑦
PLB
REVEAL (60) Gordon 2012 522 156 ADA 40mg PASI improvement
PLB




PHOENIX 1 (62) Kimball 2012 766 156 UST 45mg ④⑤⑥
UST 90mg
PLB
GO-REVEAL (63) Kavanaugh 2013 405 104 GOL 50mg ①②③④
⑤⑧⑨⑩GOL 100mg
PLB
PHOENIX 1 (64) Kimball 2013 766 260 UST 45mg ④⑤⑥
UST 90mg
PLB




PSUMMIT 1 Kavanaugh 2014 927 52 UST 45mg Radiographic progression
PSUMMIT 2 (66) UST 90mg
PLB
PSUMMIT 1 (67) Kavanaugh 2015 615 100 UST 45mg ①②③⑤
⑥⑧⑨UST 90mg
PLB
PHOENIX 2 (68) Langley 2015 1,212 260 UST 45mg ⑤⑥
UST 90mg
PLB
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TABLE 2 | Continued
Study Enrolled patients NMA
Author Year N Time of outcome
(weeks)
Drug Dosage Outcomes








(71) van der Heijde 2016 606 52 SEC 10 mg/kg Radiographic progression
SEC 75mg
SEC 150mg
PSTELLAR (72) Blauvelt 2017 325 112 UST q12 wk ⑤⑥⑦
UST q24 wk




CLEAR (74) Blauvelt 2017 676 52 SEC 300mg ⑤⑥⑦
UST 45/90mg








LIBERATE (77) Reich 2017 250 52 APR 30mg ④⑤
⑥⑩ETN 50mg
PLB




(79) Griffiths 2018 100 GUS 100mg ⑤⑥⑦
ADA 40mg
PLB




(81) Ohtsuki 2018 191 52 GUS 50mg ④⑤⑥
⑦⑩GUS 100mg
PLB




Frontiers in Medicine | www.frontiersin.org 8 January 2021 | Volume 7 | Article 618163
Torres et al. Biologic Therapy for Psoriatic Disease
TABLE 2 | Continued
Study Enrolled patients NMA









IXORA-S (84) Paul 2019 302 52 IXE 80mg ⑤⑥⑦
UST 45/90mg
SUSTaIMM (48) Ohtsuki 2019 171 52 RIS 75mg ⑤⑥⑦
RIS 150mg
PLB
N, number; NMA, network meta-analysis; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; RCT, randomized clinical trial; ADA, adalimumab;
ETN, etanercept; IFX, infliximab; GOL, golimumab; UST, ustekinumab; SEC, secukinumab; IXE, ixekizumab; GUS, guselkumab; RIS, risankizumab; APR, apremilast; TOF, tofacitinib;
PLB, placebo.
① ACR20, ② ACR50, ③ ACR70, ④ PASI50, ⑤ PASI75, ⑥ PASI90, ⑦ PASI100, ⑧ dactylitis assessment, ⑨ enthesitis assessment, ⑩ nail assessment.
FIGURE 2 | GRAPPA domains—evaluated therapies.
52 in the EXCEED study is also listed but not included on
the NMA (55).
An NMA was performed for the three outcomes (ACR20,
ACR50, and ACR70). The included studies are identified in
Table 1. A network plot for ACR70 is included in Figure 3, as
an example of the network plots of these three NMAs.
The NMA results from the network of biologic therapies for
the outcome ACR70 response are included in Table 4.
Axial Disease
Data including biologic therapies for axial disease, in the context
of PsD, are scarce, possibly because there is no validated
instrument to assess this domain. Nowadays, the only trial
addressing specifically PsD patients with the axial disease is
still ongoing and this data is not yet published. This trial—
MAXIMIZE—evaluates the efficacy and safety of SEC 300
or 150mg in managing axial manifestations in patients with
PsA, who have failed to respond to at least 2 non-steroidal
anti-inflammatory drugs (NSAIDs) over 4 weeks, according to
Assessment of Spondyloarthritis International Society (ASAS)
recommendations for the treatment of axial spondyloarthritis
(ClinicalTrials.gov NCT02721966) (86).
Enthesitis
There are at least 6 indices to evaluate enthesitis outcomes
(4-point enthesitis measure, Leeds Enthesis Index (LEI),
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TABLE 3 | ACR improvements in patients with psoriatic arthritis—peripheral disease.
Improvement
ACR20 ACR50 ACR70
Study Weeks Treatment n/total (%) n/total (%) n/total (%)
Antoni 2005
IMPACT 2 (1)
24 PLB 16/100 (16.0) 4/100 (4.0) 2/100 (2.0)
24 IFX 54/100 (54.0) 41/100 (41.0) 27/100 (27.0)
p-value <0.001 <0.001 <0.001
Mease 2005
ADEPT (11)
24 PLB 15/162 (9.3) 6/162 (3.7) 1/162 (0.6)
24 ADA 57/151 (37.7) 39/151 (25.8) 23/151 (15.2)
p-value <0.001 <0.001 <0.001
Kavanaugh 2009
(18)
24 PLB 12/113 (10.6) 1/113 (0.9) 0/113 (0)
24 GOL 75/146 (51.3) 39/146 (26.7) 25/146 (17.1)
p-value <0.001 <0.001 <0.001
McInnes 2013
PSUMMIT 1 (24)
24 PLB 47/206 (22.8) 18/206 (8.7) 5/206 (2.4)
24 UST 87/205 (42.4) 51/205 (24.8) 25/205 (12.2)
p-value <0.0001 <0.0001 0.0001
Mease 2014
RAPID-PsA (26)
24 PLB 32/136 (23.5) 17/136 (12.5) 6/136 (4.4)
24 CZP 88/138 (63.8) 60.1/138 (44.2) 39/138 (28.3)
p-value <0.001 <0.001 <0.001
Ritchlin 2014
PSUMMIT 2 (28)
24 PLB 21/104 (20.2) 7/104 (6.7) 3/104 (2.9)
24 UST 45/103 (43.7) 18/103 (17.4) 7/103 (6.8)
p-value <0.001 <0.05 n.s.
Mease 2015
FUTURE 1 (32)
24 PLB 35/202 (17.3) 15/202 (7.4) 4/202 (2.0)
24 SEC 150mg 101/202 (50.0) 70/202 (34.7) 38/202 (18.8)
p-value <0.001 <0.001 <0.001
McInnes 2015
FUTURE 2 (31)
24 PLB 15/98 (15.3) 7/98(7.1) 1/98 (1.0)
24 SEC 300 mg* 54/100 (54.0) 35/100 (35.0) 20/100 (20.0)
24 SEC 150 mg** 51/100 (51.0) 35/100 (35.0) 21/100 (21.0)
p-value *,**<0.0001 *,**<0.0001 *0.0003; **<0.0001
Mease 2017
SPIRIT P1 (37)
24 PLB 32/106 (30.2) 16/106 (15.1) 6/106 (5.7)
24 IXE Q4W* 62/107 (57.9) 43/107 (40.2) 25/107 (23.4)
24 ADA 58/101 (57.4) 39/101 (38.6) 26/101 (25.7)
p-value *≤0.001 *≤0.001 *≤0.001
Nash 2017
SPIRIT P2 (38)
24 PLB 23/118 (19.5) 6/118 (5.1) 0/118 (5.7)
24 IXE Q4W 65/122 (53.3) 43/122 (35.2) 27/122 (22.1)
p-value <0.0001 <0.0001 <0.0001
Mease 2018
FUTURE 5 (47)
24 PLB 78/332 (23.5) 29/332 (8.7) 13/332 (3.9)
24 SEC 300mg 141/222 (63.5) 97/222 (43.7) 56/222 (25.7)
SEC 150mg 117/220 (53.2) 86/220 (39.1) 53/220 (24.1)
p-value <0.0001 <0.0001 <0.0001
Mease 2020
SPIRIT H2H (51)
24 ADA 204/283 (72.1) 132/283 (46.6) 73/283 (25.8)
24 IXE 195/283 (68.9) 143/283 (50.5) 90/283 (31.8)
p-value 0.403 0.338 0.111
(Continued)
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TABLE 3 | Continued
Improvement
ACR20 ACR50 ACR70
Study Weeks Treatment n/total (%) n/total (%) n/total (%)
McInnes 2020
EXCEED (55)
52 SEC 285/426 (67) 209/426 (49) 141/426 (33)
52 ADA 252/427 (43) 192/427 (45) 124/427 (29)
p-value 0.0239 0.2251 0.2950
ACR, American College of Rheumatology; n, number; ADA, adalimumab; IFX, infliximab; GOL, golimumab; CZP, certolizumab; UST, ustekinumab; SEC, secukinumab; IXE, ixekizumab;
MTX, methotrexate; PLB, placebo *,**vs. placebo.
FIGURE 3 | Network plot of ACR70 response showing direct comparisons, at
week 24. The width of the edge is proportional to the number of studies, and
the node size is proportional to the sample size.
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES),
Spondyloarthritis Research Consortium of Canada (SPARCC)
Enthesitis Index, 12-point Berlin Index, and the 17-point
University of California, San Francisco (UCSF) Index) with no
consensus on which is the most adequate (85). Moreover, some
studies, instead of using a score, only discriminate the percentage
of patients with complete enthesitis resolution. Since different
instruments were used in different studies, it is impossible to
compare results across studies. As such, we were not able to
perform an NMA regarding this domain. A summary of the
results of the different studies is included in Table 5 (1, 13, 18,
22, 24, 26, 28, 31, 32, 37, 38, 47, 50, 51, 55, 61, 65).
Dactylitis
As enthesitis, dactylitis is also evaluated through different
approaches. It can be assessed by counting dactylitis digits—a
simple counting and scoring method or Leeds Dactylitis Index
(LDI) (85). Moreover, there is also no consensus regarding
the better method to assess dactylitis, and therefore it was not
possible to perform an NMA due to the heterogeneity found
in the different RCTs (85). Also, some studies only evaluate the
percentage of patients with complete resolution of dactylitis. A
summary of the results of the different studies is included in
Table 6 (1, 18, 24, 26, 28, 31, 32, 37, 38, 47, 51, 55, 61, 65).
Skin
Psoriasis severity was evaluated by the most used tool in
dermatology trials—PASI. PASI combines the assessment of the
severity of psoriasis lesions (average redness, thickness, and
scaliness of the lesions) and the area affected into a single
score (87). PASI is commonly reported as the percentage of
improvement from baseline, PASI75, PASI90, and PASI100,
meaning 75, 90, and 100% of improvement, respectively.
The results of the systematic review including RCTs reporting
PASI in patients with PsD, at weeks 10–16 of treatment, are
included in Table 7 (1, 11, 12, 14–16, 18–22, 25, 26, 29, 30, 33,
35–37, 39–41, 43–48, 51–53, 55–57, 59, 70).
An NMA was performed for the three outcomes: PASI75,
PASI90, and PASI100. The included studies are identified in
Table 1. A network plot for PASI100 is included in Figure 4, as
an example of the network plots of these three NMAs.
Nails
As described for enthesitis and dactylitis, the assessment of
nail psoriasis is not consensual at this time, with Nail Psoriasis
Severity Index (NAPSI) and modified NAPSI being the most
commonly used indices. Due to the low number of studies
evaluating nail psoriasis and inconsistent use of these indices, we
were not able to perform an NMA (85). A summary of the results
of the different studies is included in Table 9 (12, 18, 27, 32, 34,
36–38, 42, 46, 51, 61, 65, 69, 77, 78, 81, 88, 89).
DISCUSSION
The use of biologic therapies in the treatment of PsD is
recommended across the six domains of the disease (2). A
complete, effective, and safe treatment for all the manifestations
of PsD is the main goal in the management of this condition.
However, the heterogeneity of the manifestations challenges the
achievement of this goal.





























TABLE 4 | NMA results from the network of biologic therapies in the outcome ACR70.





















































































































































OR and CrI are presented. Comparisons with high confidence rating based on CINeMA evaluation are identified in bold and OR higher than 1 favor the intervention specified in the row.
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TABLE 5 | Enthesitis assessment in patients with psoriatic arthritis.
Study Author Year Drug Outcome Time of outcome
(weeks)
Result
IMPACT 2 (1) Antoni 2005 IFX vs. PLB Patients with enthesitis 14 22% vs. 34% (p = 0.016)
24 20% vs. 37% (p = 0.002)
(13) Genovese 2007 ADA vs. PLB Reduction of enthesitis 12 −0.5 vs. −0.2 (p > 0.05)
GO-REVEAL (18) Kavanaugh 2009 GOL 50mg vs. PLB Patients with enthesitis 14 55% vs. 71% (p = 0.008)
GOL 100mg vs. PLB 61% vs. 71% (p = 0.10)
GOL 50mg vs. PLB 24 49% vs. 69% (p = 0.002)
GOL 100mg vs. PLB 50% vs. 69% (p = 0.003)
GO-REVEAL (61) Kavanaugh 2012 GOL 50mg vs. PLB Modified MASES index
(change from baseline)
Week 52 56.3 ± 62.4 vs. 39.1 ± 76.1
GOL100mg vs. PLB 51.9 ± 64.2 vs. 39.1 ± 76.1
RESPOND (22) Baranauskaite 2012 IFX+MTX vs. MTX Reduction of enthesitis 16 2 vs. 1 (p = 0.082)
PSUMMIT 1 (24) McInnes 2013 UST vs. PLB Patients with enthesitis 24 64.6% vs. 81% (p = 0.006)
GO-REVEAL (64) Kavanaugh 2014 GOL 50mg vs. PLB Modified MASES index Week 256 1.9 ± 3.3 vs. 2.4 ± 4.0
GOL100mg vs. PLB 2.0 ± 3.4 vs. 2.4 ± 4.0
PSUMMIT 2 (28) Ritchlin 2014 UST 45mg vs. PLB MASES 24 −33,33% vs. 0% (p > 0.05)
UST 90mg vs. PLB −48.33% vs. 0% (p<0.01)
UST 45mg vs. PLB 52 −36.67% vs. −33.33% (p > 0.05)
UST 90mg vs. PLB −60% vs. −33.33% (p > 0.05)
RAPID-PsA (26) Mease 2014 CZP 200mg Q2W vs. PLB LEI 24 −2.0 vs. −1.1 (p<0.001)
CZP 400mg Q4W vs. PLB LEI −1.8 vs. −1.1 (p = 0.003)
(32) Mease 2015 SEC (pooled data) vs. PLB Resolution of enthesitis 24 47.5% vs. 12.8% (p<0.05)
FUTURE 2 (31) McInnes 2015 SEC (pooled data) vs. PLB Resolution of enthesitis 24 22% vs. 40% (p = 0.919)
SPIRIT-P1 (37) Mease 2017 IXE Q2W vs. PLB vs. ADA LEI (responders) Week 12 47.4 vs. 28.1 vs. 35.2 (p<0.05)*
IXE Q4W vs. PLB vs. ADA 27.9 vs. 28.1 vs. 35.2
IXE Q2W vs. PLB vs. ADA Week 24 38.6 vs. 19.3 vs. 33.3 (p ≤ 0.025)*
IXE Q4W vs. PLB vs. ADA 42.6 vs. 19.3 vs. 35.2 (p ≤ 0.01)*
SPITIT-P2 (38) Nash 2017 IXE Q2W vs. PLB LEI (proportion of
patients with a
response)
Week 24 31% vs. 22% (p = 0.27)
IXE Q4W vs. PLB 35% vs. 22% (p = 0.08)
FUTURE 5 (47) Mease 2018 SEC 150mg vs. PLB Resolution of enthesitis Week 16 54.6% vs. 35.4% (p < 0.05)
SEC 300mg vs. PLB 55.7% vs. 35.4% (p < 0.05)
ECLIPSA (50) Araujo 2019 UST vs. TNFi SPARCC = 0 Week 12 74% vs. 42% (p = 0.018)
MASES = 0 82% vs. 50% (p = 0.032)
LEI = 0 78% vs. 50% (p = 0.005)
SPIRIT H2H (51) Mease 2020 IXE vs. ADA SPARCC = 0 Week 24 45.0% vs. 56.6% (p = 0.019)
LEI = 0 55.1% vs. 59.7% (p = 0.432)
EXCEED (55) McInnes 2020 SEC vs. ADA resolution of enthesitis Week 52 53% vs. 50% (p = 0.5117)
ADA, adalimumab; IFX, infliximab; GOL, golimumab; CZP, certolizumab; UST, ustekinumab; SEC, secukinumab; IXE, ixekizumab; BRD, brodalumab; MTX, methotrexate; PLB, placebo;
MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; LEI, Leeds Enthesitis Index; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index; TNFi, tumor
necrosis factor inhibitor; * IXE vs. placebo.
Recent advances in the knowledge of the pathophysiology of
the disease led to the extensive study and approval of different
mechanisms of action, including TNFi such as IFX, ETN, GOL,
CZP, and ADA; IL-17i such as SEC, IXE, and BRD; and IL-12
and/or IL23i such as UST, GUS, RIS, and TIL. Nevertheless, direct
comparisons between them are scarce and therefore NMA is the
preferred method to indirectly compare drugs, aiming to help
clinicians in the choice of the best treatment.
The report of the outcomes of each GRAPPA domain is not
standardized (Tables 5, 6, 9) except for the peripheral arthritis
and skin domains, which use mainly ACR and PASI responses,
respectively (Tables 3, 7). Thus, we were only able to perform
NMAs based on ACR and PASI responses, evaluated at weeks
24 or 10–16, respectively. Although we also performed NMAs
for ACR20, ACR50, PASI75, and PASI90, based on the current
expectations on the efficacy of new biologic treatments and on the
confidence in the results, we decided to present the efficacy of the
different biologic therapy using ACR70 (Table 4) and PASI100
(Table 8), the most challenging outcomes. The confidence rating
on direct and indirect estimates was calculated using CINeMA to
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TABLE 6 | Dactylitis assessment in patients with psoriatic arthritis.
Study Author Year Intervention Outcome Time of
outcome
Result
IMPACT 2 (1) Antoni 2005 IFX vs. placebo At least 1 dactylitis digit Week 14 22% vs. 34% (p = 0.025)
Week 24 12% vs. 34% (p<0.001)
GO-REVEAL (18) Kavanaugh 2009 GOL 50mg vs. placebo Patients with dactylitis Week 14 22% vs. 26% (p = 0.46)
GOL 100mg vs. placebo 17% vs. 26% (p = 0.10)
GOL 50mg vs. placebo Week 24 16% vs. 22% (p = 0.21)
GOL 100mg vs. placebo 14% vs. 22% (p = 0.09)
GO-REVEAL (61) Kavanaugh 2012 GOL 50mg vs. placebo Dactylitis score change
from baseline
Week 52 −4.20 ± 4.81 vs. −1.68 ± 2.79
GOL 100mg vs. placebo −4.55 ± 6.60 vs. −1.68 ± 2.79
PSUMMIT 1 (24) McInnes 2013 UST vs. placebo Patients with dactylitis Week 24 56.2% vs. 76.1% (p = 0.0013)
PSUMMIT 2 (28) Ritchlin 2014 UST 45mg vs. placebo Percent change in
dactylitis score
Week 24 0.0 vs. 0.0
UST 90mg vs. placebo −64.58 vs. 0.0
UST 45mg vs. placebo Week 52 −95.00 vs. −100
RAPID-PsA (26) Mease 2014 CZP 200mg Q2W vs. placebo LDI change from
baseline
Week 24 −40.7 vs. −22.0 (p = 0.002)
CZP 400mg Q4W vs. placebo −53.5 vs. −22.0 (p<0.001)
GO-REVEAL (65) Kavanaugh 2014 GOL 50mg vs. placebo Dactylitis score Week 260 6.3 ± 6.1 vs. 3.1 ± 2.1
GOL 100mg vs. placebo 5.4 ± 6.7 vs. 3.1 ± 2.1
UST 90mg vs. placebo −90.91 vs. −100
(30) Mease 2015 SEC (pooled data) vs. placebo Resolution of dactylitis Week 24 52.4% vs. 15.5 (p<0.05)
FUTURE 2 (31) McInnes 2015 SEC (pooled data) vs. placebo Resolution of dactylitis Week 24 47% vs. 15% (p = 0.919)
SPIRIT-P1 (37) Mease 2017 IXE Q2W vs. placebo vs. ADA LDI-B (change from
baseline)
Week 12 −63.9 (10.6) vs. −36.3 (10.3) vs. −62.1 (11.9) (p ≤ 0.05)*
IXE Q4W vs. placebo vs. ADA −72.8 (8.8) vs. −36.3 (10.3) −62.1 (11.9) (p ≤ 0.001)*
IXE Q2W vs. placebo vs. ADA Week 24 −66.1 (9.8) vs. −33.7 (9.7) vs. −76.0 (10.9) (p ≤ 0.01)*
IXE Q4W vs. placebo vs. ADA −75.4 (8.1) vs. −33.7 (9.7) −76.0 (10.9) (p ≤ 0.001)*
SPIRIT-P2 (38) Nash 2017 IXE Q2W vs. placebo LDI-B (change from
baseline)
Week 24 −32.1 (6.7) vs. −36.2 (8.4) p = 0.65
IXE Q4W vs. placebo −34.7 (6.7) VS. −36.2 (8.4) p = 0.85
FUTURE 5 (47) Mease 2018 SEC 150mg vs. placebo Resolution of dactylitis Week 16 57.5% vs. 32.3% (p < 0.05)
SEC 300mg vs. placebo 65.9% vs. 32.3% (p < 0.05)
SPIRIT H2H (51) Mease 2020 IXE vs. ADA LDI-B = 0 Week 24 88.1 vs. 93.1 (p = 0.658)
EXCEED (55) McInnes 2020 SEC vs. ADA Resolution of dactylitis Week 52 75% vs. 70% (p = 0.3560)
ADA, adalimumab; IFX, infliximab; GOL, golimumab; CZP, certolizumab; UST, ustekinumab; SEC, secukinumab; IXE, ixekizumab; BRD, brodalumab; PLB, placebo; LDI, Leeds Dactylitis
Index; *IXE vs. placebo.
improve the transparency and limit the subjectivity of the process
(90–92). Comparisons with a high confidence rating, based on
the CINeMA evaluation (91), are represented in bold. The level of
confidence of the other comparisons is either low or very low, and
consequently, the surface under the cumulative rating (SUCRA)
will result in misleading inferences (90, 93). Thus, a SUCRA was
not done and, therefore, it was impossible to rank the available
biologic treatments.
In the ACR70 NMA (Table 4), the results of the comparisons
between drugs are not reliable, except when compared with
the placebo. From the 12 RCTs reporting ACR70 responses
at week 24 (Table 3) (1, 11, 18, 24, 26, 28, 31, 32, 37, 38,
49, 51), only one performed head-to-head comparisons, at
week 24, and there was no superiority regarding this specific
endpoint (51). The other head-to-head study is EXCEED,
with a primary endpoint at 52 weeks, showing also no
superiority regarding ACR70. Nevertheless, and as expected,
compared with the placebo, all drugs were significantly better in
achieving ACR20/50/70.
In the PASI100 response NMA (Table 8), as for ACR70, the
comparisons with high confidence levels were few and therefore
it was not possible to rank the drugs regarding their probability
to achieve differences in PASI100 between weeks 10 and 16.
The comparisons with placebo were reliable, and the drugs that
lead to a higher probability in achieving PASI100 were BRD,
RIS, IXE, and GUS. Although based on CINeMA analysis we
were not able to have high confidence in all of our comparisons,
the results from placebo comparison were partially following
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TABLE 7 | PASI Improvements in patients with psoriasis skin.
Improvement
PASI75 PASI90 PASI100
Study Weeks Drug n/total (%) n/total (%) n/total (%)
Antoni 2005 14 PLB 1/87 (1.0) 0/87 (0.0) –
IMPACT 2 (1) 14 IFX 55/87 (64.0) 34/87 (41.0) –
p-value <0.001 <0.001
Mease 2005 12 PLB 4/69 (5.8) 0/69 (0.0) –
ADEPT (11) 12 ADA 49/69 (71.0) 30/69 (43.5) –
p-value <0.001 <0.001
Reich 2005 10 PLB 2/77 (3.0) 1/77 (1.0) –
(12) 10 IFX 242/301 (80.0) 172/301 (57.0) –
p-value <0.0001 <0.0001
Tyring 2007 12 PLB 5/292 (1.7) 1/292 (0.3) –
(13) 12 ETA 47/305 (15.4) 21/305 (6.9) –
p-value <0.001 <0.001
Leonardi 2008 12 PLB 5/255 (2.0) 5/255 (2.0) 0/255 (0.0)
PHOENIX 1 (15) 12 UST 45mg 171/255 (67.0) 106/255 (41.6) 32/255 (12.5)
p-value <0.0001 <0.0001 <0.0001
Menter 2008 12 PLB 20/398 (5.0) 8/398 (2.0) 4/398 (1.0)
(59) 12 ADA 554/814 (68.1) 301/814 (37.0) 114/814 (14.0)
p-value <0.001 <0.001 <0.001
Papp 2008 12 PLB 15/410 (3.7) 3/410 (0.7) 0/410 (0.0)
PHOENIX 2 (16) 12 UST 45mg 273/409 (66.5) 173/409 (42.3) 74/409 (18.1)
p-value <0.0001 <0.0001 <0.0001
Kavanaugh 2009 14 PLB 2/79 (2.5) 0/73 (0.0) –
(18) 14 GOL 50mg 44/109 (40.3) 22/106 (20.8) –
p-value <0.001 <0.001
Barker 2011 16 MTX 90/216 (41.7) 41/216 (19.0) –
RESTORE1 (19) 16 IFX 508/656 (77.4) 356/656 (54.2) –
p-value n.s. <0.001
Gottlieb 2011 12 PLB 5/68 (7.4) 1/68 (1.5) 0/68 (0.0)
(20) 12 BRK* 112/138 (81.0) 83/138 (60.0) 39/138 (28.3)
12 ETA 78/141 (55.0) 18/141 (12.7) 5/141 (3.6)
p-value <0.001 <0.001 <0.001
Strober 2011 12 PLB 5/72 (6.9) 3/72 (4.2) 0/72 (0.0)
(20) 12 BRK* 111/139 (80.0) 83/139 (60) 30/139 (21.9)
12 ETA 40/139 (28.8) 18/139 (13.0) 5/139 (3.6)
p-value <0.001 <0.001 <0.001
Baranauskaite 2012 16 MTX 19/35 (54.3%) – –
RESPOND (22) 16 MTX+IFX 33/34 (97.1%) – –
p-value <0.0001 – –
Langley 2014 12 PLB 11/246 (4.5) 3/246 (1.2) 2/246 (0.8)
ERASURE (25) 12 SEC 300mg 200/245 (81.6) 145/245 (59.2) 70/245 (26.6)
p-value <0.001 <0.001 <0.001
Langley 2014 12 PLB 16/324 (4.9) 5/324 (1.5) 0/324 (0.0)
FIXTURE (25) 12 SEC 300 mg* 249/323 (77.0) 175/323 (54.1) 78/323 (24.1)
12 ETA 142/323 (44.0) 67/323 (20.7) 14/323 (4.3)
p-value <0.001 <0.001 <0.001
Mease 2014 12 PLB 12/86 (13.9) 4/86 (4.7) –
RAPID-PsA (26) 12 CZP 200mg 42/90 (46.7) 20/90 (22.2) –
p-value <0.001 <0.001
(Continued)
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TABLE 7 | Continued
Improvement
PASI75 PASI90 PASI100
Study Weeks Drug n/total (%) n/total (%) n/total (%)
Griffiths 2015
UNCOVER 2 (29)
12 PLB 4/168 (2.4) 1/168 (0.6) 1/168 (0.6)
12 IXE Q4W* 269/347 (77.5) 267/347 (76.9) 107/347 (30.8)
12 ETA 149/358 (41.6) 67/358 (18.7) 19/358 (5.3)
p-value <0.0001 <0.0001 <0.0001
Griffiths 2015
UNCOVER 3 (29)
12 PLB 14/193 (7.2) 6/193 (3.1) 0/193 (0.0)
12 IXE* 325/386 (84.2) 352/386 (91.2) 135/386 (35.0)
12 ETA 201/382 (52.6) 98/382 (25.6) 19/358 (5.3)
p-value <0.0001 <0.0001 <0.0001
Lebwohl 2015 12 PLB 25/309 (8.1) 12/309 (3.9) 2/309 (0.6)
AMAGINE 2 (30) 12 UST 210/300 (70.0) 141/300 (47.0) 65/300 (21.7)
12 BRD 210 mg* 528/612 (86.3) 428/612 (69.9) 272/612 (44.4)
p-value <0.001 <0.001 <0.001
Lebwohl 2015 12 PLB 19/315 (6.0) 6/315 (1.9) 1/315 (0.3)
AMAGINE 3 (30) 12 UST 217/313 (69.3) 141/313 (45.0) 58/313 (18.5)
12 BRD* 531/624 (85.1) 430/624 (68.9) 229/624 (36.7)
p-value <0.001 <0.001 <0.001
Thaci 2015 12 SEC 311/334 (93.1) 264/334 (79.0) 148/334 (44.3)
CLEAR (33) 12 UST 277/334 (82.9) 277/334 (82.9) 130/334 (38.9)
p-value <0.0001 <0.0001 =0.003
Gordon 2016 12 PLB 17/431 (3.9) 7/431 (1.7) 0/431 (0.0)
UNCOVER 1 (70) 12 IXE Q4W 357/432 (82.6) 279/432 (64.6) 145/432 (33.6)
p-value <0.001 <0.001 <0.001
Papp 2016 12 PLB 6/220 (2.7) 2/220 (0.9) 1/220 (0.5)
(35) 12 BRD 185/222 (83.3) 156/220 (70.9) 93/222 (41.9)
p-value <0.001 <0.001 <0.001
Blauvelt 2017 16 PLB 10/174 (5.7) 5/174 (2.9) 1/174(0.6)
VOYAGE 1 16 GUS* 300/329 (91.2) 241/329 (73, 3) 123/329 (37.4)
(36) 16 ADA 244/334 (73.1) 166/334 (49.7) 57/334 (17.4)
p-value <0.001 <0.001 <0.001
Mease 2017 12 PLB 5/67 (7.5) 1/67 (1.5) 1/67 (1.5)
SPIRIT 1 12 IXE Q4W* 55/73 (75.3) 38/73 (52.0) 23/73 (31.5)
(37) 12 ADA 23/68 (33.8) 15/68 (22.1) 10/68 (14.7)
p-value ≤0.01 ≤0.01 ≤0.01
Reich 2017 12 PLB 9/154 (5.8) 4/154 (3.0) 2/154 (1.3)
reSURFACE 1 (39) 12 TIL 100mg 197/309 (63.8) 107/309 (35.0) 43/309 (13.9)
p-value <0.0001 <0.0001 <0.0001
Reich 2017 12 PLB 9/156 (5.8) 2/156 (1.3) 0/156 (0.0)
reSURFACE 2 (39) 12 TIL 100 mg* 188/307 (61.2) 119/307 (38.8) 38/307 (12.4)
12 ETA 151/313 (48.2) 67/313 (21.4) 15/313 (4.8)
p-value 0.0001 0.0001 0.0001
Reich 2017 12 IXE 120/136 (88.2) 99/136 (72.8) 49/136 (36.0)
IXORA-S (40) 12 UST 114/166 (68.7) 70/166 (42, 2) 24/166 (14.5)
p-value 0.001 0.001 0.001
Bagel 2018 16 SEC 504/550 (91.7) 421/550 (76.6) 249/550 (45.3)
CLARITY (41) 16 UST 440/552 (79.8) 299/552 (54.1) 147/552 (26.7)
p-value <0.0001 <0.0001 <0.0001
Gordon 2018 12 PLB 10/102 (9.8) 2/102 (2.0) 0/102 (0.0)
(Continued)
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TABLE 7 | Continued
Improvement
PASI75 PASI90 PASI100
Study Weeks Drug n/total (%) n/total (%) n/total (%)
UltiMMa 1 (43) 12 UST* 70/100 (70) 42/100 (42.0) 12/100 (12.0)
12 RIS* 264/304 (86.8) 229/304 (75.3) 109/304 (35.9)
p-value <0.0001 <0.0001 <0.0001
Gordon 2018 12 PLB 8/98 (8.1) 2/98 (2.0) 2/98 (2.0)
UltiMMa 2 (43) 12 UST 69/99 (69.7) 47/99 (47.5) 24/99 (24.2)
12 RIS 261/294 (88.8) 220/294 (74.9) 149/294 (50.7)
p-value <0.0001 <0.0001 <0.0001
Gottlieb 2018 16 PLB 3/51 (6.5) 0/51 (0.0) 0/51 (0.0)
CIMPASI 1 (44) 16 CZP 200mg 63/95 (66.3) 34/95 (35.8) 13/95 (13.7)
p-value <0.0001 <0.0001 <0.0001
Gottlieb 2018 16 PLB 6/49 (11.6) 2/49 (2.2) 1/49 (1.8)
CIMPASI 2 (44) 16 CZP 200mg 74/92 (81.4) 48/91 (52.6) 14/91 (15.4)
p-value <0.0001 <0.0001 <0.0001
Lebwohl 2018 16 PLB 3/57 (5.3) 5/57 (0.0) –
CIMPACT (45) 16 CZP 200mg 113/165 (68.5) 66/165 (40.0) –
p-value <0.0001 <0.0001
Reich 2018 16 PLB 3/65 (4.6) 1/65 (1.5) 0/65 (0.0)
TRANSFIGURE (46) 16 SEC 300mg 56/66 (84.8) 48/66 (72.7) 22/66 (33.3)
p-value <0.001 <0.001
Mease 2018 16 PLB 40/332 (12.3) 31/332 (9.3) –
FUTURE 5 (47) 16 SEC 150mg 132/220 (60.0) 81/220 (36.8) –
16 SEC 300mg 155/222 (70.0) 119/222 (53.6) –
p-value <0.05 <0.05
Reich 2019 16 RIS 150mg 237/301 (91) 218/301 (72) 120/301 (40)
IMMvent (52) 16 ADA 218/304 (72) 144/304 (47) 70/304 (23)
p-value <0.0001 <0.0001 <0.0001
Reich 2019 12 GUS 477/534 (89) 369/534 (69) 311/534 (58)
ECLIPSE (53) 12 SEC 471/514 (92) 391/514 (76) 249/514 (48)
p-value NA NA NA
Ohtsuki 2019
SustaIMM (48)
16 RIS 75 mg* 52/58 (89.8) – 13/58 (22.4)
16 RIS 150 mg* 52/55 (94.5) – 18/55 (32.7)
16 PLB 5/58 (8.6) – 0/0
p-value <0.001 <0.001
Mease 2020 16 ADA 195/238 (68.9) 158/283 (55.8) 132/283 (46.6)
SPIRIT H2H (51) 16 IXE 227/283 (80.2) 203/283 (71.7) 170/283 (60.1)
p-value p = 0.002 <0.001 <0.001
McInnes 2020 52 SEC 170/215 (79) 140/215 (54) 99/215 (46)
EXCEED (55) 52 ADA 123/202 (61) 87/202 (43) 61/202 (30)
p-value 0.0002 <0.0001 0.0007
Ferris 2020 16 GUS 55/62 (88.7) 47/62 (75.8) 31/62 (50.0)
ORION (56) 16 PLB 0/16 (0) 0/16 (0) 0/16 (0)
p-value <0.001 <0.001 <0.001
Warren 2020 16 RIS 92/164 (56.1) 74/164 (45.1) 44/164 (26.9)
IMMerge (57) 16 SEC 80/163 (49.1) 66/163 (40.5) 34/163 (20.9)
PASI, Psoriasis Area Severity Index; ADA, adalimumab; ETN, etanercept; IFX, infliximab; GOL, golimumab; CZP, certolizumab; UST, ustekinumab; SEC, secukinumab; IXE, ixekizumab;
GUS, guselkumab; BRD, brodalumab; RIS, risankizumab; TIL, tildrakizumab; BRK, briakinumab; MTX, methotrexate; PLB, placebo; *vs. placebo.
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FIGURE 4 | Network plot of PASI100 showing direct comparisons, at weeks
10–16. The width of the edge is proportional to the number of studies, and the
node size is proportional to the sample size.
recently published network meta-analysis (94–96). Although the
number of RCTs reporting PASI100 response (Table 7) (15,
16, 20, 21, 25, 29, 30, 33, 35–37, 39–41, 43, 44, 46, 48, 51–
53, 56, 57, 59, 70) as an outcome was superior to the ones
reporting ACR70 response, the confidence in the NMA was not
superior. Since 2015 some head-to-head trials were designed
to evaluate the efficacy of specific drugs in the PASI response
outcome (33, 40, 41, 51–53, 55, 57), and significant differences
were found (Table 7).
A complete treatment of a patient with PsD should be ideally
based on a single drug that is effective in all the manifestations.
Currently, from the therapies included in the PASI100 NMAs,
only ADA, CZP, IXE, SEC, and UST were approved for PSO
and PsA. Thus, in integrative analysis of NMA results, and
based only on comparisons of the drugs with placebo, those
with the highest probability of reaching the proposed outcome
for skin and joint domains are SEC and IXE. For SEC, OR
(95% CrI) are 9.430 (5.455, 16.302) and 42.897 (26.848, 68.539)
versus placebo for ACR70 and PASI100, respectively. For IXE,
OR are 9.315 (4.206, 20.627) and 64.027 (39.805, 102.997)
versus placebo for ACR70 and PASI100, respectively. Even
though a few previous NMAs analyzed treatment options in
PsD including ACR and PASI outcomes, most of them did not
find significant differences in the efficacy and safety between the
drugs, only detecting that treatments were more efficacious than
placebo (97–101).
As reported in Table 5, data regarding the enthesitis domain
were not so consistent as skin and peripheral arthritis results
(1, 13, 18, 22, 24, 26, 28, 31, 32, 37, 38, 47, 50, 51, 55, 61, 65, 76).
In addition to the outcome not being standardized, there were
studies reporting more than one outcome without consistent
results (50, 51). There were drugs that even in comparison with
the placebo did not show a consistent significant benefit (22,
28, 31, 38, 76). Long-term evaluation of enthesitis showed that
the benefit was maintained with IFX at week 54 (58). Although
the benefit of UST was not consistent at weeks 24 and 52(28),
at week 100 there was a 100% improvement of MASES from
baseline (67) and the same was true for SEC results, which
showed inconsistent data at week 24 (31, 32), but at week 104
there was 100% resolution of enthesitis in 70% of the patients
who had enthesitis at baseline (75). Enthesopathy affects 35–
50% of patients with PsA and should be managed carefully
since it can affect the quality of life and work productivity
even in the early stages of the disease (102). A recent study
showed that enthesitis is the phenotypes of PsD that contribute
most to Quality of Life Scores and that this domain should be
evaluated, bilaterally, in all PsD patients, particularly in those
referring joint pain (103). Nevertheless, the clinical evaluation
of enthesitis is not standardized and lacks accuracy and the
reliability is highly dependent on the observer (104). A recent
study compared MASES, SPARCC, and LEI, the three enthesitis
index, and showed that MASES had a better correlation with
disease activity and functional measures (105). On the other
hand, another study has reported a better performance in LEI
and SPARCC indices, which showed a higher discriminatory
ability and treatment responses suggested to be related to the
fact that MASES evaluates fewer peripheral sites, which may
be clinically relevant in the context of PsA, a predominantly
peripheral disease (106).
Similarly to enthesitis, the outcomesmeasured in the dactylitis
domain were not standardized as is explicit in Table 6 (1, 18,
24, 26, 28, 31, 32, 37, 38, 47, 51, 55, 61, 76). Moreover, there
were data with the same drug in different studies that were
not consistent (31, 32, 37, 38). Long-term data showed that the
benefit with IFX was maintained at week 54 (58). For UST, the
median percent improvement in the enthesitis score at week
100 was 100% (67) whereas for SEC treatment 90% of the
patients presented complete dactylitis resolution at week 104
(75). A major limitation in dactylitis evaluation is that physical
examination is the basis for the clinical assessment of dactylitis
and imaging tools have been used only to complement the clinical
examination. Nevertheless, the criteria for image resolution are
not uniform and therefore data from different studies are not
comparable (107, 108). Like enthesitis, dactylitis also has a
huge impact on the quality of life and in the structural impact
of PsD, and data from enthesitis and dactylitis highlight the
difficulty in treating these manifestations and the long period
of treatment that is needed to achieve remission. Recently, a
real-world PsA population multinational study has shown that
enthesitis, dactylitis, inflammatory back pain, and sacroiliitis
are significantly associated with the worsening of the patient’s
quality of life and/or work productivity, through evaluation of an
extensive patient-reported outcomes (PROs) list—namely EQ-
5D, HAQ-DI, Psoriatic Arthritis Impact of Disease (PsAID)12,
and Work Productivity and Activity Impairment (WPAI) (109).





























TABLE 8 | NMA results from the network of biologic therapies in the outcome PASI100.









































































































































































































































































OR and CrI are presented. Comparisons with high confidence rating based on CINeMA evaluation are identified in bold. OR higher than 1 favor the intervention specified in the row.
NMA, network meta-analysis; PASI, Psoriasis Area Severity Index; CINeMA, Confidence in Network Meta-Analysis; OR, odds ratio; CrI, credible interval; ADA, adalimumab; ETN, etanercept; IFX, infliximab; GOL, golimumab; CZP,
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TABLE 9 | Nail psoriasis assessment in patients with psoriasis.
Study Author Year Intervention Outcome Time of
outcome
Result
(12) Reich 2005 IFX vs. placebo Percentage of
improvement NAPSI
Week 10 26.0 (42.3) vs. −5.9 (54.3) (p < 0.0001)
Week 24 56.3 (43.3) vs. −3.2 (62.3) (p < 0.0001)
(18) Kavanaugh 2009 GOL 50mg vs. placebo Percentage of
change NAPSI
Week 14 25% vs. 0% (p = 0.015)
GOL 100mg vs. placebo 53% vs. 0% (p < 0.001)
GOL 50mg vs. placebo Week 24 33% vs. 0% (p < 0.001)
GOL 100mg vs. placebo 54% vs. 0% (p < 0.001)
GO-REVEAL (61) Kavanaugh 2012 GOL 50mg vs. placebo NAPSI (percentage
change from
baseline)
Week 52 51.6 ± 46.8 vs. 56.2 ± 48.1
GOL 100mg vs. placebo 65.8 ± 51.9 vs. 56.2 ± 48.1
Ortonne 2013 ETN 50mg BIW NAPSI Week 12 −13.6 (−16.7 to −10.5)
ETN 50mg QW −15.7 (−19,0 to −12.5)
PHOENIX 1 (27) Rich 2014 UST 45mg vs. placebo NAPSI baseline score Week 12 26.7% vs. 11.8% (p < 0.001)
UST 90mg vs. placebo 24.9% vs. 11.8% (p < 0.001)
UST 45mg vs. placebo Week 24 46.5% vs. 29.1%
(65) Kavanaugh 2014 GOL 50mg vs. placebo NAPSI Week 256 1.7 ± 2.5 vs. 1.1 ± 1.9
GOL 100mg vs. placebo 1.1 ± 1.8 vs. 1.1 ± 1.9




(26) Mease 2015 CZP 200mg Q2W vs. placebo mNAPSI change from
baseline
Week24 – 1.6 VS. −1.1 (p = 0.003)
CZP 400mg Q4W vs. placebo −2.0 vs. −1.1 (p < 0.001)
UNCOVER 3 (69) Dennehy 2016 IXE Q2W vs. placebo vs. ETN Improvement in nail
psoriasis
Week 12 38% vs. 28% vs. −4.7%
IXE Q4W vs. placebo vs. ETN 40% vs. 48% vs. −4,7%
SPIRIT-P1 (37) Mease 2017 IXE Q2W vs. placebo vs. ADA NAPSI Week 12 −7.7 (1.4) vs. −1.1 (1.4) vs. −6.8 (1.4) p < 0.05*
IXE Q4W vs. placebo vs. ADA −15.5 (1.5) vs. −2.4 (1.7) vs. −10.7 (1.5)
p < 0.05*
IXE Q2W vs. placebo vs. ADA Week 24 −8.4 (1.5) vs. −1.1 (1.4) vs. −6.8 (1.4) p < 0.05*
IXE Q4W vs. placebo vs. ADA −14.0 (1.5) 2.4 (1.7) vs. −10.7 (1.5) p < 0.05*
SPIRIT-P2 (38) Nash 2017 IXE Q2W vs. placebo Proportion of patients
who had a response
Week 24 34.8% vs. 11.0% (p < 0.0005)
IXE Q4W vs. placebo 20% vs. 7.0% (p < 0.0001)
UNCOVER 3 (78) van der
Kerkhof
2017 IXE Q2W vs. placebo NAPSI from baseline Week 12 35.2% vs. −34.3% p < 0.001
IXE Q4W vs. placebo 36.7% vs. −34.3% p < 0.001
IXE Q2W vs. ETN 35.2 (6.9) vs. 20.0 (5.9) p > 0.005
IXE Q4W vs. ETN 36.7% vs. 20% p = 0.048
IXE Q2W vs. placebo NAPSI = 0 Week 12 17.5% vs. 4.3% p < 0.001
IXE Q4W vs. placebo 19.7% vs. 4.3% p < 0.001
IXE Q2W vs. ETN 17.5% vs. 10.2% p < 0.05
IXE Q4W vs. ETN 19.7% vs. 10.2% p < 0.05
(36) Blauvelt 2017 GUS vs. placebo vs. ADA NAPSI percent
improvement
Week 16 34.4 ± 42.46 vs. −0.9 ± 57.89 vs. 38.0 ± 53.87
p < 0.001**
GUS vs. ADA Week 24 49.8 ± 44.16 vs. 49.4 ± 60.04
GUS vs. ADA Week 48 68.1 ± 43.00 vs. 61.4 ± 49.20
(Continued)
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TABLE 9 | Continued
Study Author Year Intervention Outcome Time of
outcome
Result
LIBERATE (77) Reich 2017 APR vs. placebo NAPSI (percentage of
change)
Week 16 −18.7 (40.2) vs. −17.0 (25.0) p = 0.4959
ETN vs. placebo −35.9 (28.9) vs. −17.0 (25.0) p = 0.0024
(42) Elewski 2018 ADA vs. placebo mNAPSI75 Week 26 46.6% vs. 3.4% (p < 0.001)
Improvement NAPSI Week 26 56.2% vs. 11.5% (p < 0.01)
UST 90mg vs. placebo 48.7% vs. 29.1%
(81) Ohtsuki 2018 GUS 50mg vs. placebo Change in NAPSI Week 16 −1.2 (1.61) vs. −0.2 (1.13) p < 0.001
GUS 100mg vs. placebo −1.5 (1.78) vs. −0.2 (1.13) p < 0.001
TRANSFIGURE (46) Reich 2018 SEC 150mg vs. placebo NAPSI (percentage of
change)
Week 16 −37.9% vs. −10.8% (p < 0.001)
SEC 300mg vs. placebo −45.3% vs. −10.8% (p < 0.001)






SPIRIT H2H (51) Mease 2020 IXE vs. ADA Fingernails
NAPSI = 0
Week 24 58.1% vs. 71.7% (p < 0.001)
ADA, adalimumab; ETN, etanercept; IFX, infliximab; GOL, golimumab; CZP, certolizumab; UST, ustekinumab; SEC, secukinumab; IXE, ixekizumab; GUS, guselkumab; RIS, risankizumab;
PLB, placebo; NAPSI, Nail Psoriasis Severity Index; mNAPSI, modified Nail Psoriasis Index. *IXE vs. placebo, **GUS vs. placebo.
Inflammatory back pain and sacroiliitis are common axial
manifestations in PsA patients and can arise in 30 to 70%
of patients (110, 111). There is an ongoing discussion on
whether axial manifestations in PsA are equivalent to those
seen in axial spondyloarthritis and consequently if they may
be treated in the same way (112). In fact, the evidence of
the efficacy of biologic therapies in the PsA axial domain
is still scarce. However, some studies and case reports have
suggested a positive impact of TNFi, IL-17i, and IL-12/23i in
axial involvement-related outcomes in PsD patients, namely,
BASDAI and ASAS-PR, showing that it could be possible
to achieve remission and minimal disease activity (113–
115). To our knowledge, the only randomized clinical trial
addressing treatment efficacy in this specific domain patient
profile is theMAXIMIZE trial (ClinicalTrials.gov NCT02721966)
(86)—a study evaluating SEC efficacy in axial manifestations
improvement in PsA patients. In fact, from the data released
in the latest international congresses, results suggest that IL-
17 inhibition, namely, with SEC, is effective in axial PsA
treatment, evaluated by ASAS response and Berlin MRI
score (116).
Nail psoriasis is common among patients with moderate-
to-severe PsO and more prevalent in patients with PsA (117).
Different studies assessed the efficacy of biologic agents in the
treatment and resolution of nail psoriasis (Table 9) (12, 18,
26, 27, 34, 37, 38, 42, 46, 51, 61, 65, 69, 73, 77, 78, 81, 88).
All of them showed the benefit of the tested drug compared
to the placebo. The head-to-head comparison between IXE
and ADA showed superiority at week 24 of IXE (51). The
response is sustained in long-term studies (46, 69, 81). Of
note, most studies reporting NAPSI represent subgroup analysis
including recruited patients who had manifestations of nail
psoriasis. However, from the data described there are only
drugs with studies designed specifically to evaluate nail Psoriasis:
ETN (89), ADA (42), and SEC (46). Importantly, these studies
were specifically designed to evaluate nail outcomes and have
demanding recruitment criteria, with NAPSI scores more severe
and, therefore, muchmore difficult to treat. Therefore, the results
obtained with these 3 drugs may be considered more robust and
significant concerning their impact on nail treatment. Of note, all
studies demonstrated an improvement in the evaluated scores.
However, scores and time points were not the same, making
comparisons impossible.
Taking all the results from the systematic review and network
meta-analysis together in Figure 2, IL-17i are the drugs tested
in more manifestations, namely, SEC that had specific studies
for all the domains, even though axial domain data were not
yet published.
This result is in line with what was recently published in two
NMA (98, 118). The first one concluded that SEC demonstrated
good efficacy across the evaluated outcomes (ACR, PASI, and
PsARC at 12–16 weeks) and all the treatments demonstrated
superiority to placebo (98). The other study demonstrated that
SEC may be the most efficacious and the safest biologic for
short-term treatment of PsA (118).
Limitations
One of the main limitations of this study is the high
variability of study designs, inclusion and exclusion
criteria, and patients’ characteristics. It is important to
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note that for enthesitis, dactylitis, and nail psoriasis the
evaluated outcomes are heterogeneous and do not allow the
performance of a network meta-analysis. The results of the
NMAs highlight the limitations of this method, and caution
is needed in the interpretation of these results to avoid
misleading inferences.
CONCLUSIONS
PsD is a very complex disease in which the same patient
may present several manifestations with a great impact
on functional and quality of life. Nowadays, we should
be more demanding in the analysis of therapeutic
outcomes, focusing on achieving remission in all
PsD manifestations.
Although there are several effective therapies, this study
showed that the concept of a holistic and efficacious treatment for
patients with PsD is achievable and that IL-17i are the drugs most
extensively tested in this context. Specifically, SEC demonstrated
good efficacy in all the evaluated GRAPPA domains, allowing
a complete short-term treatment for patients with multiple
manifestations of the disease.
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